Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

88,779 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

Hydroxypropyl methyl cellulose and extended release matrix system

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,878
1.WO/2004/016249EXTENDED RELEASE MATRIX TABLETS
WO - 26.02.2004
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No PCT/IB2003/003269 Applicant RANBAXY LABORATORIES LIMITED Inventor JAIN, Girish, Kumar
The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. The active pharmaceutical ingredient may be one or more of antibiotics, sympathomimetics, sympatholytic agents, cholinergic agents, antimuscarinics, gastro-intestinal drugs, gentio-urinary smooth muscle relaxants, cardiac drugs, anticonvulsants, tranquilizers and sedatives, and in particular may be an antibiotic, such as cefaclor, or may be a sympatholytic agent, such as carvedilol.
2.WO/2008/073388ALFUZOSIN FORMULATIONS, METHODS OF MAKING AND METHODS OF USE
WO - 19.06.2008
Int.Class A61K 9/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
 Appl.No PCT/US2007/025260 Applicant MUTUAL PHARMACEUTICAL COMPANY, INC. Inventor ARNOLD, Kristin
Alfuzosin compositions comprising alfuzosin and a release-retarding matrix comprising about 40 to about 80 % (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 are disclosed. Alfuzosin compositions comprising alfuzosin and a release-retarding matrix comprising about 40 to about 80 % (by weight) hydroxypropyl methyl cellulose (HPMC) with a maximum apparent viscosity of about 5600 cP, wherein the dissolution profile of the compositions are substantially identical to the dissolution profile of the reference dosage form of NDA #021287 are also disclosed. Methods of making and using the alfuzosin compositions are also disclosed.
3.WO/2004/096182EXTENDED RELEASE MATRIX TABLETS OF CARVEDILOL
WO - 11.11.2004
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No PCT/IB2004/001268 Applicant RANBAXY LABORATORIES LIMITED Inventor JAIN, Girish, Kumar
The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, x such a methacrylic acid derivative with a dimethylaminoethyl ammonium group such as a water-swellable cellulose derivative and an alginic acid derivative to cause the release rate of the active ingredient of the talbets to be S independent of pH and gastric residence time. The present invention also relates to a dual release matrix tablet of carvedilol. The pharmaceutical composition includes carvedilol formulated into an extended release core wherein a portion of the core is surrounded by a second immediate release layer of carvedilol.
4.WO/2008/004001THE USE OF PVP TO CONTROL THE RELEASE PROFILE OF AN ACTIVE INGREDIENT FROM A HYDROPHILIC POLYMER MATRIX TABLET
WO - 10.01.2008
Int.Class A61K 9/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
 Appl.No PCT/GB2007/050375 Applicant MERCK SHARP & DOHME LIMITED Inventor HARDY, Ian
The invention relates to the use of polyvinyl pyrrolidone (PVP) for the modulation of drug release kinetics from hydrophilic polymer matrix tablets, in particular hydroxypropyl methyl cellulose (HPMC) matrix tablets. Another aspect of the invention is a method of drug release from a hydrophilic polymer matrix tablet, for example a hydroxypropyl methyl cellulose (HPMC) and compositions thereof.
5.5378/DELNP/2005EXTENDED RELEASE MATRIX TABLETS OF CARVEDILOT
IN - 02.10.2009
Int.Class A61K /
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
 Appl.No 5378/DELNP/2005 Applicant RANBAXY LABORATORIES LIMITED Inventor GIRISH KUMAR JAIN
A dual release matrix tablet of carvedilol for oral administration comprising(a) a extended release matrix core comprising carvedilol, water swellable cellulose derivative, alginic acid derivative, and cationic polymer; and(b) immediate release layer comprising carvedilol and film fomriing agent002E
6.697/DELNP/2005EXTENDED RELEASE MATRIX TABLES
IN - 07.12.2007
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No 697/DELNP/2005 Applicant RANBAXY LABORATORIES LIMITED Inventor GIRISH KUMAR JAIN
The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time.
7.20060159752Extended release matrix tablets
US - 20.07.2006
Int.Class A61K 31/736
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
736Glucomannans or galactomannans, e.g locust bean gum, guar gum
 Appl.No 10524461 Applicant JAIN GIRISH K Inventor Jain Girish Kumar

The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. The active pharmaceutical ingredient may be one or more of antibiotics, sympathomimetics, sympatholytic agents, cholinergic agents, antimuscarinics, gastro-intestinal drugs, gentio-urinary smooth muscle relaxants, cardiac drugs, anticonvulsants, tranquilizers and sedatives, and in particular may be an antibiotic, such as cefaclor, or may be a sympatholytic agent, such as carvedilol.

8.20100092556ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE
US - 15.04.2010
Int.Class A61K 9/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
 Appl.No 12419721 Applicant ARNOLD KRISTIN Inventor Arnold Kristin

Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core comprising a release-retarding coating material, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 (UROXATRAL) are disclosed. Methods of making and using the alfuzosin compositions are also disclosed.

9.20080160081ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE
US - 03.07.2008
Int.Class A61K 9/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
 Appl.No 11953181 Applicant MUTUAL PHARMACEUTICAL COMPANY, INC. Inventor Naringrekar Gandha V.

Alfuzosin compositions comprising alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 are disclosed. Alfuzosin compositions comprising alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose (HPMC) with a maximum apparent viscosity of about 5600 cP, wherein the dissolution profile of the compositions are substantially identical to the dissolution profile of the reference dosage form of NDA #021287 are also disclosed. Methods of making and using the alfuzosin compositions are also disclosed.

10.388/MUM/2010EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF NIFEDIPINE
IN - 17.02.2012
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
 Appl.No 388/MUM/2010 Applicant UNICHEM LABORATORIES LIMITED Inventor DR. GEDALA VENKATA MURALI MOHAN BABU
The present invention relates to the field of pharmaceutical technology and describes about extended release pharmaceutical composition which is simple and cost effective. It also provides methods of manufacturing of extended release solid oral dosage forms comprising nifedipine. This composition taken orally in the treatment of hypertension and angina.
# -